Skip Ribbon Commands
Skip to main content
 
New Studies

Checkpoint inhibition for treating Hodgkin and Non-Hodgkin lymphoma in allo HSCT

Pneumocystis Pneumonia (PcP) after allo HSCT

***

Checkpoint inhibition for treating Hodgkin and Non-Hodgkin lymphoma in the context of allogeneic stem cell transplantation: A survey-based registry study of the EBMT Lymphoma Working Party.

 

This study aims to investigate safety and efficacy of immune checkpoint inhibitor treatment before and after allogeneic stem cell transplantation in NHL and HL.

For more information about the Lymphoma Working Party and about this study, please click HERE

To fill in the survey please click HERE


***

 

A case-control study on risk factors, timing, and PCR use, for pneumocystis pneumonia (PcP) after allogeneic HSCT: A non-interventional prospective study of the EBMT Infectious Diseases Working Party.

This study aims to identify pre- and post-transplant factors associated with development of PcP after allogeneic HSCT.

For more information about the Infectious Diseases Working Party and about this study, please click HERE

 

 

 News

 
18/01/2017
January 2017 | Volume 55 - Issue 1... Read more >>
05/10/2016
​EBMT TV returns to 2017 Annual Meeting... Read more >>
26/09/2016
​The EBMT has contributed to the Innovative Medicines Intiative... Read more >>
10/05/2016
​More than 60 EBMT centres have already started entering their related donor data. We want to invite... Read more >>
 

 Events

 
Bookmark and Share